Select the name of the type of clinical care program you would like more information about …

Example: ‘B’ for Bladder Cancer

Cancer Treatment A-Z

Skip to content. | Skip to navigation

Personal tools

Navigation

You are here: Home / Members / Joel Parker
Joel  Parker

Joel Parker

  • Ph.D.
  • Cancer Genetics

  • School of Medicine
  • UNC-Chapel Hill
  • parkerjs@email.unc.edu
  • 966-9614
  • 450 West Drive, Lineberger Cancer Center

Area of Interest

The Lineberger Bioinformatics Core provides the infrastructure for management and analysis of large scale research projects, and promotes individual researchers to tap the ever-growing data generated by new cancer research technologies. The mission of the bioinformatics core is to support and enhance LCCC research activities by providing bioinformatics services and support.
The Lineberger Bioinformatics Core is currently involved in multiple projects where the goal is integrated analysis of genomic data. Our role in these collaborations is to allow LCCC PIs to mine relevant information from their data, and leverage public data for their own experiments. We are also experienced in integrating clinical data with genomics for association testing. This work has led to development of clinically relevant diagnostic assays, their evaluation with public data, and validation in clinical trial cohorts.
Other current research is focused on development and evaluation of algorithms to process sequence data from high throughput sequencing technologies and aid in interpretation of results. This effort is exemplified in two large scale projects, The Cancer Genome Atlas (TCGA) and UNCseq. As part of TCGA, the bioinformatics core is responsible for processing and public dissemination of RNA sequence and expression for over four thousand tumor specimens, a subset of which are described in recent series of high profile manuscripts. The UNCseq study aims to associate known molecular alterations with clinical outcomes in oncology and use this information to support treatment decisions through reporting of genetic profiling to clinicians. The technologies used in this project are under continued development and evaluation with a goal of translation to the molecular pathology laboratories at UNC Hospitals.